Defendant

Jazz Pharmaceuticals Ireland Limited

5 cases as defendant.

Cases
5
Active
1
4 closed
Filed
2016–2022
Top venue
D. Delaware
1 case
Also appears as a plaintiff in 8 cases → View as plaintiff

Company profile

I'll verify the company's profile with web searches.

Jazz Pharmaceuticals Ireland Limited is an Irish operating subsidiary of Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a Dublin-headquartered biopharmaceutical company founded in 2003. The parent reported roughly 2,890 employees and about $4.0–4.3 billion in FY2024 revenue, with a market capitalization in the $10–15 billion range; it is publicly traded, not an NPE or shell entity. (Sources: Jazz investor filings/10-K, PitchBook, MarketWatch.)

Operations. Jazz develops and commercializes prescription medicines in neuroscience and oncology. Key products include the oxybate franchise (Xywav and Xyrem) for narcolepsy and idiopathic hypersomnia; Epidiolex/Epidyolex (cannabidiol) for rare epilepsies, acquired via the 2021 GW Pharmaceuticals acquisition; and oncology therapies including Rylaze, Zepzelca, Vyxeos, Defitelio and Ziihera. Revenue is split roughly between neuroscience and oncology.

Litigation posture. This is an operating company and an active two-way litigant, with 8 plaintiff and 5 defendant tracked cases. Most plaintiff suits are Hatch-Waxman/ANDA and 505(b)(2) actions defending Orange Book-listed patents against generic challengers (Tris Pharma, Granules, Teva, Lupin, Roxane), concentrated in the District of New Jersey. Defendant appearances come from competitor and government actions rather than NPE assertions.

Notable cases. Jazz's oxybate patent disputes with Avadel CNS Pharmaceuticals (Delaware and the Federal Circuit) are prominent, as is the ongoing generic-oxybate litigation listed above. It was also a defendant in a qui tam suit, United States ex rel. Leonardo Sorgi v. Jazz Pharmaceuticals PLC (D. Mass., 2021), and in a PTAB proceeding brought by Ranbaxy. No plaintiff-friendly venue clustering (e.g., E.D. Texas) appears in the tracked data.

Note: several tracked case entries list affiliate entities ("Jazz Pharmaceuticals, Inc./PLC") rather than the Ireland entity by name; the Ireland entity is the group's Irish operating/marketing subsidiary.

Filing activity

2016: 1 case'16'17'18'19'202021: 1 case'212022: 2 cases2'22
Cases filed per year naming Jazz Pharmaceuticals Ireland Limited as defendant.

Avadel CNS Pharmaceuticals, LLC et al. v. Jazz Pharmaceuticals, Inc. et al.

dismissed with prejudice (settled)
Docket:
1:22-cv-00487-GBW
Filed:
2022-04-14
Terminated:
2025-10-27
Patents:11147782

Avadel's affirmative trade-secrets and inventorship action; Avadel alleged Jazz used confidential information and sought correction of inventorship of certain Jazz patents, including the '782 patent. Dismissed with prejudice on October 27, 2025 pursuant to settlement.

Avadel CNS Pharmaceuticals, LLC et al. v. Jazz Pharmaceuticals, Inc. et al.

dismissed
Docket:
1:22-cv-00487-GBW
Filed:
2022-04-14
Terminated:
2025-10-27

Avadel-side Delaware action in which Flamel/Avadel asserted their modified-release GHB patent family, including U.S. 10,272,062 and 10,736,866 (parents of the '986 patent) and U.S. 10,952,986, against Jazz. The case was consolidated and dismissed by order on 2025-10-27 as part of the settlement.

United States ex rel. Leonardo Sorgi v. Jazz Pharmaceuticals PLC et al.

active
Docket:
1:21-cv-10891-PBS
Filed:
2021-05-27
Patents:8772306

Collateral False Claims Act case concerning the '306 patent. Relator alleges Jazz defrauded the PTO in obtaining the '306 patent; the United States and several states declined to intervene, an amended complaint was filed Sept 1, 2024, and Jazz's motion to dismiss was filed Dec 2, 2024, with oral argument Apr 2, 2025.

Ranbaxy Inc. v. Jazz Pharmaceuticals Ireland Limited

terminated by settlement
Docket:
IPR2016-00738
Court:
PTAB
Filed:
2016-03-10
Terminated:
2016-05-23
Patents:9050302

Ranbaxy Inc. filed an IPR against Jazz Pharmaceuticals Ireland Limited concerning U.S. Patent 9,050,302. The proceeding was terminated by settlement, with termination judgment entered May 23, 2016.

Avadel CNS Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc. et al.

decided; reversed-in-part, vacated-in-part, remanded
Docket:
2024-2274, 2024-2277, 2024-2278
Terminated:
2025-05-06
Patents:11147782

Consolidated Federal Circuit appeal from D. Del. Nos. 1:21-cv-00691-GBW, 1:21-cv-01138-GBW, and 1:21-cv-01594-GBW concerning the permanent injunction in the '782 patent dispute. The Federal Circuit reversed-in-part, vacated-in-part, and remanded on May 6, 2025.